Evidence map›Paper›PMID 28810149›Full record

ArticleCancer cell2017

O

Joshua D Schoenfeld, Zita A Sibenaller, Kranti A Mapuskar, Brett A Wagner, Kimberly L Cramer-Morales, Muhammad Furqan, Sonia Sandhu, Thomas L Carlisle, Mark C Smith, Taher Abu Hejleh and 25 more

Registry-linked trialAbstract readPublished Erratum
PubMed Publisher
In one paragraph

Article in Cancer cell, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06493370 (Intravenous Ascorbate Plus Gemcitabine/Carboplatin), which is not on this map. Cited by 67 papers.

0numbers the graph read from it
0cells of the map it votes in
67citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06493370 phase2recruitingnot on this mapstarted 2025, after this paper: background citation

Intravenous Ascorbate Plus Gemcitabine/Carboplatin: A Novel and Cost-Effective Alternative With Evident Efficacy in Patients With Muscle Invasive Bladder Cancer

TypeinterventionalSponsorUniversity of Kansas Medical CenterRan2025 to 2030Enrolled48ConditionsBladder CancerArmsIntravenous ascorbic acid/vitamin C
3 · Its place in the literature

Who cites it

67 citing papers in PubMed.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Metabolic targeting of malignant tumors: a need for systemic approach.Journal of cancer research and clinical oncology · 2023
    Review
  19. Article
  20. Article

7 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

  • Erratum for
    O2017
5 · Who and what money

Authors and funding

35 authors.

Joshua D Schoenfeld
Zita A Sibenaller
Kranti A Mapuskar
Brett A Wagner
Kimberly L Cramer-Morales
Muhammad Furqan
Sonia Sandhu
Thomas L Carlisle
Mark C Smith
Taher Abu Hejleh
Daniel J Berg
Jun Zhang
John Keech
Kalpaj R Parekh
Sudershan Bhatia
Varun Monga
Kellie L Bodeker
Logan Ahmann
Sandy Vollstedt
Heather Brown
Erin P Shanahan Kauffman
Mary E Schall
Ray J Hohl
Gerald H Clamon
Jeremy D Greenlee
Matthew A Howard
Michael K Schultz
Brian J Smith
Dennis P Riley
Frederick E Domann
Joseph J Cullen
Garry R Buettner
John M Buatti
Douglas R Spitz
Bryan G Allen

Funding

Pulmonary Toxicology Facility CoreP30ES005605 · NIEHS · UNIVERSITY OF IOWA · PI Jong Sung Kim · 1990 to 2026
$40.5M
MEDICAL SCIENTIST TRAINING PROGRAMT32GM007337 · NIGMS · UNIVERSITY OF IOWA · PI GEYER, PAMELA K., LENTZ, STEVEN R · 1985 to 2020
$15.9M
Mitochondrial Targeted Metastatic Melanoma TherapyK25CA172218 · NCI · UNIVERSITY OF IOWA · PI SCHULTZ, MICHAEL KING · 2013 to 2017
$753k
NCI NIH HHS K25 CA172218NIEHS NIH HHS P30 ES005605NIGMS NIH HHS T32 GM007337
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.